Exactly right. Nobody is interested in bisantrene as a less cardiotoxic alternative to doxorubicin, they are interested because they can keep using doxorubicin and gain the potential of cardioprotection and increased anticancer activity.
While the data Moleculin have presented is very interesting, the market doesn't seem to care and their MC is only US$10m.
- Forums
- ASX - By Stock
- RAC
- Cardioprotection thread
Cardioprotection thread, page-406
-
-
- There are more pages in this discussion • 500 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.65 |
Change
0.050(3.13%) |
Mkt cap ! $281.1M |
Open | High | Low | Value | Volume |
$1.63 | $1.70 | $1.52 | $318.0K | 193.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 496 | $1.65 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 5484 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 496 | 1.650 |
1 | 22586 | 1.645 |
1 | 200 | 1.640 |
1 | 17732 | 1.630 |
1 | 25000 | 1.550 |
Price($) | Vol. | No. |
---|---|---|
1.700 | 5484 | 2 |
1.720 | 581 | 1 |
1.745 | 12136 | 1 |
1.750 | 26309 | 3 |
1.755 | 990 | 1 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online